Low mRNA expression of the apoptosis-related genes CASP3, CASP8, and FAS is associated with low induction treatment response in childhood Acute Lymphoblastic Leukemia (ALL)

Pediatric Blood and Cancer

Volumn 55, Issue 1, 2010, Pages 100-107

  Mata, Juliana F ^a,b   Silveira, Vanessa S ^a   Mateo, Elvis C ^a   Cortez, Maria A A ^a   Queiroz, Rosane G P ^a   Yunes, José Andrés ^c   Lee, Maria Lúcia M ^d   Toledo, Sílvia R C ^d   Petrilli, Antonio Sérgio ^d   Brandalise, Silvia R ^c,e   Tone, Luiz G ^a   Scrideli, Carlos A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b BARRETOS CANCER HOSPITAL   (Brazil)

^c CENTRO INFANTIL BOLDRINI   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

ALL; Apoptosis; Children; Survival

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; FAS ANTIGEN; MESSENGER RNA; PROTEIN BCL 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; APOPTOSIS; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RISK; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; EVENT FREE SURVIVAL; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; ANTIGENS, CD95; CASPASE 3; CASPASE 8; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOPHENOTYPING; INFANT; LEUKOCYTE COUNT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SURVIVAL RATE;

EID: 77953250077     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22463     Document Type: Article

References (32)

1. Schimmer AD. Apoptosis in leukemia: From molecular pathways to targeted therapies. Best Pract Res Clin Haematol 2008;21:5-11.
2. Meyer LH, Karawajew L, Schrappe M, et al. Cytochrome c-related caspase-3 activation determines treatment response and relapse in childhood precursor B-cell ALL. Blood 2006;107:4524-4531. (Pubitemid 43801381)
3. Solary E, Droin N, Bettaieb A, et al. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. Leukemia 2000;14:1833-1849.
4. Iannolo G, Conticello C, Memeo L, et al. Apoptosis in normal and cancer stem cells. Critical Rev Oncol/Hematol 2008;66:42-51.
5. Schimmer AD, Hedley DW, Penn LZ, et al. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: A translational view. Blood 2001;98:3541-3553.
6. Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 2004;53:153-159.
7. Faderl S, Thall P, Kantarjian H, et al. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res 1999;5:4041-4047. (Pubitemid 30013782)
8. Oliver L, Vavasseur F, Mahe B, et al. Assessment of caspase activity as a possible prognostic factor in acute myeloid leukaemia. Brit J Haematol 2002;118:434-437. (Pubitemid 34994645)
9. Svingen PA, Karp JE, Krajewski S, et al. Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. Blood 2000;96:3922-3931.
10. Kornblau SM, Thall PF, Estrov Z, et al. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 1999;5:1758-1766. (Pubitemid 29334457)
11. Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: A population based study. J Clin Oncol 1996;14:2131-2138. (Pubitemid 26230116)
12. Meyer LH, Queudeville M, Eckhoff SM, et al. Intact apoptosis signaling in myeloid leukemia cells determines treatment outcome in childhood AML. Blood 2008;111:2899-2903.
13. Coustan-Smith E, Kitanaka A, Pui CH, et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 1996;87:1140-1146. (Pubitemid 26043542)
14. Prokop A, Wieder T, Sturm I, et al. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 2000;14:1606-1613.
15. Liu T, Raetz E, Moos PJ, et al. Diversity of the apoptotic response to chemotherapy in childhood leukemia. Leukemia 2002;16:223-232. (Pubitemid 34145140)
16. Suminoe A, Matsuzaki A, Hattori H, et al. mRNA expression of apoptosis-associated genes in infant acute lymphoblastic leukemia: Low Fas expression is an independent predictor for poor prognosis. Leukemia 2004;18:365-368. (Pubitemid 38240059)
17. Robinson BW, Behling KC, Gupta M, et al. Abundant antiapoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation. Br J Haematol 2008;141:827-839. (Pubitemid 351724853)
18. Scrideli CA, Assumpção JG, Ganazza MA, et al. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups. Haematologica 2009;94:781-789.
19. -ΔDelta;Ct method. Methods 2001;25:402-408.
20. Stanulla M, Cario G, Meissner B, et al. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia-a perspective from the BFM Study Group. Blood Cells Mol Dis 2007;39:160-163. (Pubitemid 47126931)
21. Estrov Z, Thall PF, Talpaz M, et al. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood 1998;92:3090-3097. (Pubitemid 28492314)
22. Testa U, Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica 2007;92:81-94. (Pubitemid 46237556)
23. Schimmer AD, Pedersen IM, Kitada S, et al. Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy. Cancer Res 2003;63: 1242-1248. (Pubitemid 36348701)
24. Aref S, Salama O, Al-Tonbary Y, et al. Assessment of bcl-2 expression as modulator of fas mediated apoptosis in acute leukemia. Hematology 2004;9:113-121. (Pubitemid 38697025)
25. Wuchter C, Karawajew L, Ruppert V, et al. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia 1999;13: 1943-1953.
26. Baryshnikov A, Polosukhina ER, Tupitsin NN, et al. CD95 (FAS/APO-1) antigen is a new prognostic marker of blast cells of acute lymphoblastic leukaemia patients. Adv Exp Med Biol 1999;457: 251-258. (Pubitemid 129735318)
27. Wuchter C, Karawajew L, Ruppert V, et al. Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia. Br J Haematol 2000;110:154-160. (Pubitemid 30625603)
28. Campos L, Rouault JP, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993;81:3091-3096. (Pubitemid 23162130)
29. Laudanski J, Chyczewski L, Niklinska WE, et al. Expression of bcl-2 protein in non-small cell lung cancer: Correlation with clinicopathology and patient survival. Neoplasma 1999;46:25-30. (Pubitemid 29166935)
30. Charpin C, Garcia S, Bonnier P, et al. bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: Correlation with 10-year follow-up. J Clin Oncol 1998;16:2025-2031. (Pubitemid 28265036)
31. Droin N, Dubrez L, Eymin B, et al. Upregulation of CASP genes in human tumor cells undergoing etoposide-induced apoptosis. Oncogene 1998;16:2885-2894. (Pubitemid 28383273)
32. Holleman A, den Boer ML, de Menezes RX, et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 2006;107:769-776. (Pubitemid 43076404)